Publication Cover
Amyloid
The Journal of Protein Folding Disorders
Volume 23, 2016 - Issue 3
809
Views
77
CrossRef citations to date
0
Altmetric
Review Article

Insulin amyloid at injection sites of patients with diabetes

Pages 139-147 | Received 05 Feb 2016, Accepted 13 Apr 2016, Published online: 09 May 2016

References

  • Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014;21:221–4.
  • Selivanova OM, Galzitskaya OV. Structural polymorphism and possible pathways of amyloid fibril formation on the example of insulin protein. Biochem Mosc 2012;77:1237–47.
  • Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 2001;40:6036–46.
  • Hjorth CF, Norrman M, Wahlund PO, Benie AJ, Petersen BO, Jessen CM, Pedersen TA, et al. Structure, aggregation, and activity of a covalent insulin dimer formed during storage of neutral formulation of human insulin. J Pharm Sci 2016;105:1376–86.
  • Devlin GL, Knowles TP, Squires A, McCammon MG, Gras SL, Nilsson MR, Robinson CV, et al. The component polypeptide chains of bovine insulin nucleate or inhibit aggregation of the parent protein in a conformation-dependent manner. J Mol Biol 2006;360:497–509.
  • Nielsen L, Frokjaer S, Brange J, Uversky VN, Fink AL. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry 2001;40:8397–409.
  • Kurouski D, Washington J, Ozbil M, Prabhakar R, Shekhtman A, Lednev IK. Disulfide bridges remain intact while native insulin converts into amyloid fibrils. PLoS One 2012;7:e36989.
  • Ahmad A, Millett IS, Doniach S, Uversky VN, Fink AL. Partially folded intermediates in insulin fibrillation. Biochemistry 2003;42:11404–16.
  • Ivanova MI, Sievers SA, Sawaya MR, Wall JS, Eisenberg D. Molecular basis for insulin fibril assembly. Proc Natl Acad Sci USA 2009;106:18990–5.
  • Li Y, Gong H, Sun Y, Yan J, Cheng B, Zhang X, Huang J, et al. Dissecting the role of disulfide bonds on the amyloid formation of insulin. Biochem Biophys Res Commun 2012;423:373–8.
  • Gupta Y, Singla G, Singla R. Insulin-derived amyloidosis. Indian J Endocrinol Metab 2015;19:174–7.
  • Iwasa S, Enomoto A, Onoue S, Nakai M, Yajima T, Fukushima T. Chromatographic analysis of conformationally changed insulin and its cytotoxic effect on PC12 cells. J Health Sci 2009;55:825–31.
  • Wang SS, Liu KN, Han TC. Amyloid fibrillation and cytotoxicity of insulin are inhibited by the amphiphilic surfactants. Biochim Biophys Acta 2010;1802:519–30.
  • Murali J, Koteeswari D, Rifkind JM, Jayakumar R. Amyloid insulin interaction with erythrocytes. Biochem Cell Biol 2003;81:51–9.
  • Dische FE, Wernstedt C, Westermark GT, Westermark P, Pepys MB, Rennie JA, Gilbey SG, et al. Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia 1988;31:158–61.
  • Nagase T, Iwaya K, Iwaki Y, Kotake F, Uchida R, Oh-i T, Sekine H, et al. Insulin-derived amyloidosis and poor glycemic control: a case series. Am J Med 2014;127:450–4.
  • Yoshizaki T, Honda M. Insulin absorption in a patient with local subcutaneous amyloid deposition. J Japan Diab Soc 2012;55:786–92.
  • Nagase T, Katsura Y, Iwaki Y, Nemoto K, Sekine H, Miwa K, Oh IT, et al. The insulin ball. Lancet 2009;373:184.
  • De Coninck C, Frid A, Gaspar R, Hicks D, Hirsch L, Kreugel G, Liersch J, et al. Results and analysis of the 2008–2009 insulin injection technique questionnaire survey. J Diabetes 2010;2:168–79.
  • Shikama Y, Kitazawa J, Yagihashi N, Uehara O, Murata Y, Yajima N, Wada R, et al. Localized amyloidosis at the site of repeated insulin injection in a diabetic patient. Intern Med 2010;49:397–401.
  • Surmacz-Chwedoruk W, Nieznanska H, Wojcik S, Dzwolak W. Cross-seeding of fibrils from two types of insulin induces new amyloid strains. Biochemistry 2012;51:9460–9.
  • Albert SG, Obadiah J, Parseghian SA, Yadira Hurley M, Mooradian AD. Severe insulin resistance associated with subcutaneous amyloid deposition. Diabetes Res Clin Pract 2007;75:374–6.
  • D'Souza A, Theis JD, Vrana JA, Buadi F, Dispenzieri A, Dogan A. Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate. Am J Hematol 2012;87:E131–2.
  • Maji SK, Schubert D, Rivier C, Lee S, Rivier JE, Riek R. Amyloid as a depot for the formulation of long-acting drugs. PLoS Biol 2008;6:e17.
  • Jimenez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR. The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci USA 2002;99:9196–201.
  • Storkel S, Schneider HM, Muntefering H, Kashiwagi S. Iatrogenic, insulin-dependent, local amyloidosis. Lab Invest 1983;48:108–11.
  • Lougheed WD, Woulfe-Flanagan H, Clement JR, Albisser AM. Insulin aggregation in artificial delivery systems. Diabetologia 1980;19:1–9.
  • Hutchison KG. Assessment of gelling in insulin solutions for infusion pumps. J Pharm Pharmacol 1985;37:528–31.
  • Renard E, Baldet P, Picot MC, Jacques-Apostol D, Lauton D, Costalat G, Bringer J, et al. Catheter complications associated with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors, and obstructing materials. Diabetes Care 1995;18:300–6.
  • van Dijk PR, Logtenberg SJ, Groenier KH, Haveman JW, Kleefstra N, Bilo HJ. Complications of continuous intraperitoneal insulin infusion with an implantable pump. World J Diabetes 2012;3:142–8.
  • Dische FE, Wernstedt C, Westermark GT, Westermark P, Pepys MB, Gilbey SG, Watkins PJ. Localized deposition of an insulin-containing amyloid in a diabetic at sites of repeated injections of porcine insulin. J Pathol 1987;152:194A.
  • Swift B. Examination of insulin injection sites: an unexpected finding of localized amyloidosis. Diabet Med 2002;19:881–2.
  • Ciin LCH, Barker D. Unexpected finding of amyloidosis at the site of insulin injection. Pract Diab Int 2005;22:118.
  • Lonsdale-Eccles AA, Gonda P, Gilbertson JA, Haworth AE. Localized cutaneous amyloid at an insulin injection site. Clin Exp Dermatol 2009;34:e1027–8.
  • Yumlu S, Barany R, Eriksson M, Rocken C. Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. Hum Pathol 2009;40:1655–60.
  • Endo JO, Rocken C, Lamb S, Harris RM, Bowen AR. Nodular amyloidosis in a diabetic patient with frequent hypoglycemia: sequelae of repeatedly injecting insulin without site rotation. J Am Acad Dermatol 2010;63:E113–14.
  • Sie MP, van der Wiel HE, Smedts FM, de Boer AC. Human recombinant insulin and amyloidosis: an unexpected association. Neth J Med 2010;68:138–40.
  • Kayser O, Order BM, Schäfer F. Die insulininduzierte, lokale amyloidose der brust-eine seltene differenzialdiagnose zum DCIS und mammakarzinom; amyloid tumor of the breast casued by s.c. injections of insulin - a rare differential diagnosis of DCIS and breast carcinoma. Geburtshilfe Frauenheilkd 2011;71:606–8.
  • Kudo-Watanuki S, Kurihara E, Yamamoto K, Mukai K, Chen KR. Coexistence of insulin-derived amyloidosis and an overlying acanthosis nigricans-like lesion at the site of insulin injection. Clin Exp Dermatol 2013;38:25–9.
  • Okamura S, Hayashino Y, Kore-Eda S, Tsujii S. Localized amyloidosis at the site of repeated insulin injection in a patient with type 2 diabetes. Diabetes Care 2013;36:e200.
  • D'Souza A, Theis JD, Vrana JA, Dogan A. Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration. Amyloid 2014;21:71–5.
  • Damm F, Goerdt S, Schmieder A. Localized insulin-dependent amyloidosis with scar-tissue formation. J Am Acad Dermatol 2014;71:e160–2.
  • Nandeesh BN, Rajalakshmi T, Shubha B. Cutaneous amyloidosis and insulin with coexistence of acanthosis nigricans. Indian J Pathol Microbiol 2014;57:127–9.
  • Bernardez C, Scharer L, Molina-Ruiz AM, Requena L. Nodular amyloidosis at the sites of insulin injections. J Cutan Pathol 2015;42:496–502.
  • Gilbertson JA, Hunt T, Wechalekar AD, Lachmann HJ, Hawkins PN, Gillmore JD. Localised amyloid at injection sites derived from porcine and human insulin. Amyloid 2010;17:124.
  • Grunes D, Rapkiewicz A, Simsir A. Amyloidoma secondary to insulin injection: cytologic diagnosis and pitfalls. Cytojournal 2015;12:15.
  • Vrana JA, Theis JD, Dasari S, Mereuta OM, Dispenzieri A, Zeldenrust SR, Gertz MA, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica 2014;99:1239–47.
  • Yabe S, Takahashi H, Gotoda H, Mori T, Ikawa H, Kudo H, Matsumoto A, et al. A case of type 1 diabetes mellitus with marked poor glycemic control caused by insulin-derived amyloidosis at the site of repeated insulin injections. J Japan Diab Soc 2015;58:34–40.
  • Kusuki K, Yoshizaki T, Takeda T, Honda M. The analysis of the histology, image findings, and insulin absorption about subcutaneous masses which occurred in insulin injection sites. J Japan Diab Soc 2015;58:388–97.
  • Lasagna-Reeves CA, Clos AL, Midoro-Hiriuti T, Goldblum RM, Jackson GR, Kayed R. Inhaled insulin forms toxic pulmonary amyloid aggregates. Endocrinology 2010;151:4717–24.
  • Executive summary: standards of medical care in diabetes. Diabetes Care 2012;35:S4–S10.
  • Berger M, Cuppers HJ, Hegner H, Jorgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care 1982;5:77–91.
  • Wallymahmed ME, Littler P, Clegg C, Haqqani MT, Macfarlane IA. Nodules of fibrocollagenous scar tissue induced by subcutaneous insulin injections: a cause of poor diabetic control. Postgrad Med J 2004;80:732–3.
  • Jockel JP, Roebrock P, Shergold OA. Insulin depot formation in subcutaneous tissue. J Diabetes Sci Technol 2013;7:227–37.
  • Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component. A critical review. Amyloid 1997;4:274–95.
  • Wei BP, Somers GR, Castles L. Dystrophic calcification and amyloidosis in old subcutaneous injection sites. ANZ J Surg 2003;73:556–8.
  • Ramdas S, Ramdas A, Ambroise M. Insulin injection site dystrophic calcification with fat necrosis: a case report of an uncommon adverse effect. J Family Med Prim Care 2014;3:269–71.
  • Strauss K, De Gols H, Hannet I, Partanen T-M, Frid A. A pan-European epidemiologic study of insulin injection technique in patients with diabetes. Pract Diab Int 2002;19:71–6.
  • Yamashiro K, Takahashi C, Kamimura S, Iida N, Yokota A, Inagaki H, Ishida K, et al. The importance of subcutaneous mass detection in insulin injection sites and the guidance of site rotation. J Japan Diab Soc 2015;58:439–45.
  • Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 2013;39:445–53.
  • Fujikura J, Fujimoto M, Yasue S, Noguchi M, Masuzaki H, Hosoda K, Tachibana T, et al. Insulin-induced lipohypertrophy: report of a case with histopathology. Endocr J 2005;52:623–8.
  • Soudan B, Girardot C, Fermon C, Verlet E, Pattou F, Vantyghem MC. Extreme subcutaneous insulin resistance: a misunderstood syndrome. Diabetes Metab 2003;29:539–46.
  • Chantelau EA, Berger M. Pollution of insulin with silicone oil, a hazard of disposable plastic syringes. Lancet 1985;1:1459.
  • Chantelau E, Berger M, Bohlken B. Silicone oil released from disposable insulin syringes. Diabetes Care 1986;9:672–3.
  • Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci 2005;94:918–27.
  • Baldwin RN. Contamination of insulin by silicone oil: a potential hazard of plastic insulin syringes. Diabet Med 1988;5:789–90.
  • Bernstein RK. Clouding and deactivation of clear (regular) human insulin: association with silicone oil from disposable syringes? Diabetes Care 1987;10:7867.
  • Webster RC, Hamdan US, Gaunt JM, Fuleihan NS, Smith RC. Rhinoplastic revisions with injectable silicone. Arch Otolaryngol Head Neck Surg 1986;112:269–76.
  • Gill HS, Prausnitz MR. Does needle size matter? J Diabetes Sci Technol 2007;1:725–9.
  • Juul KA, Bengtsson H, Eyving B, Kildegaard J, Lav S, Poulsen M, Serup J, et al. Influence of hypodermic needle dimensions on subcutaneous injection delivery - a pig study of injection deposition evaluated by CT scanning, histology, and backflow. Skin Res Technol 2012;18:447–55.
  • Webster GT, Dusting J, Balabani S, Blanch EW. Detecting the early onset of shear-induced fibril formation of insulin in situ. J Phys Chem B 2011;115:2617–26.
  • Feingold V, Jenkins AB, Kraegen EW. Effect of contact material on vibration-induced insulin aggregation. Diabetologia 1984;27:373–8.
  • Li S, Leblanc RM. Aggregation of insulin at the interface. J Phys Chem B 2014;118:1181–8.
  • Becton Dickinson. A look at the reuse of insulin needles. Available from: http://www.bd.com/us/diabetes/download/Reuse_White_Paper.pdf [last accessed 28 Jan 2016].
  • Blatherwick NR, Bischoff F, Maxwell LC, Berger J, Sahyun M. Studies on insulin. J Biol Chem 1927;72:57–89.
  • Waugh DF. A fibrous modification of insulin. I. The heat precipitate of insulin. J Am Chem Soc 1946;68:247–50.
  • Brange J. Stability of insulin: studies on the physical and chemical stability of insulin in pharmaceutical formulation. Boston: Kluwer Academic Publishers; 1994.
  • Heldt CL, Sorci M, Posada D, Hirsa A, Belfort G. Detection and reduction of microaggregates in insulin preparations. Biotechnol Bioeng 2011;108:237–41.
  • Becton Dickinson. How to store and handle insulin. Available from: http://www.bd.com/us/diabetes/page.aspx?cat=7001&id=7247 [last accessed 7 Mar 2016].
  • Woods RJ, Alarcon J, McVey E, Pettis RJ. Intrinsic fibrillation of fast-acting insulin analogs. J Diabetes Sci Technol 2012;6:265–76.
  • King S. First Word Lists: Blockbuster diabetes drugs 2014 and 2020. Available from: http://www.firstwordpharma.com/node/1282421 - axzz42FFbQCOq [last accessed 7 Mar 2016].
  • Weber C, Kammerer D, Streit B, Licht AH. Phenolic excipients of insulin formulations induce cell death, pro-inflammatory signalling and MCP-1 release. Toxicol Rep 2015;2:194–202.
  • O'Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 2004;279:17490–9.
  • Oskarsson ME, Paulsson JF, Schultz SW, Ingelsson M, Westermark P, Westermark GT. In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am J Pathol 2015;185:834–46.
  • Morales R, Green KM, Soto C. Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol Disord Drug Targets 2009;8:363–71.
  • Jaikaran ET, Nilsson MR, Clark A. Pancreatic beta-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem J 2004;377:709–16.
  • Wilhelm KR, Yanamandra K, Gruden MA, Zamotin V, Malisauskas M, Casaite V, Darinskas A, et al. Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. Eur J Neurol 2007;14:327–34.
  • Schwartz K, Syed AK, Stephenson RE, Rickard AH, Boles BR. Functional amyloids composed of phenol soluble modulins stabilize Staphylococcus aureus biofilms. PLoS Pathog 2012;8:e1002744.
  • van Faassen I, Razenberg PP, Simoons-Smit AM, van der Veen EA. Carriage of Staphylococcus aureus and inflamed infusion sites with insulin-pump therapy. Diabetes Care 1989;12:153–5.
  • HeathWarehouse.com. Available from: http://www.healthwarehouse.com [last accessed 4 Jan 2016].
  • Centers for Disease Control and Prevention. National diabetes statistics report: Estimates of diabetes and its burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.